Treats relapsing forms of multiple sclerosis (MS). ANDA 208000, held by Dr Reddys. Fingolimod Hydrochloride.
As of Nov 16, 2026, ANDA 208000 (Fingolimod Hydrochloride), held by Dr Reddys, was first approved by FDA on Mar 5, 2021, with 3 approved supplements and 0 published complete response letters.
Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 5, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fingolimod HydrochlorideEQ 0.5MG BASE · capsule;oral | Fingolimod Hydrochloride | Rx |
| Jan 22, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 15, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 15, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 5, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters